Currently Viewing:
The American Journal of Managed Care May 2015
Comparison of Provider and Plan-Based Targeting Strategies for Disease Management
Ann M. Annis, MPH, RN; Jodi Summers Holtrop, PhD, MCHES; Min Tao, PhD; Hsiu-Ching Chang, PhD; and Zhehui Luo, PhD
Making Measurement Meaningful
Christine K. Cassel, MD, President and CEO, National Quality Forum
Care Fragmentation, Quality, and Costs Among Chronically Ill Patients
Brigham R. Frandsen, PhD; Karen E. Joynt, MD, MPH; James B. Rebitzer, PhD; and Ashish K. Jha, MD, MPH
Results From a National Survey on Chronic Care Management by Health Plans
Soeren Mattke, MD, DSc; Aparna Higgins, MA; and Robert Brook, MD, ScD
Association Between the Patient-Centered Medical Home and Healthcare Utilization
Rainu Kaushal, MD, MPH; Alison Edwards, MStat; and Lisa M. Kern, MD, MPH
Transforming Oncology Care: Payment and Delivery Reform for Person-Centered Care
Kavita Patel, MD, MS; Andrea Thoumi, MSc; Jeffrey Nadel, BA; John O'Shea, MD, MPA; and Mark McClellan, MD, PhD
True "Meaningful Use": Technology Meets Both Patient and Provider Needs
Heather Black, PhD; Rodalyn Gonzalez, BA; Chantel Priolo, MPH; Marilyn M. Schapira, MD, MPH; Seema S. Sonnad, PhD; C. William Hanson III, MD; Curtis P. Langlotz, MD, PhD; John T. Howell, MD; and Andrea J. Apter, MD, MSc
Innovative Care Models for High-Cost Medicare Beneficiaries: Delivery System and Payment Reform to Accelerate Adoption
Karen Davis, PhD, APN; Christine Buttorff, PhD; Bruce Leff, MD; Quincy M. Samus, PhD; Sarah Szanton, PhD, APN; Jennifer L. Wolff, PhD; and Farhan Bandeali, MSPH
Currently Reading
Annual Diabetic Eye Examinations in a Managed Care Medicaid Population
Elham Hatef, MD, MPH; Bruce G. Vanderver, MD, MPH; Peter Fagan, PhD; Michael Albert, MD; and Miriam Alexander, MD, MPH
Changing Trends in Type 2 Diabetes Mellitus Treatment Intensification, 2002-2010
Rozalina G. McCoy, MD; Yuanhui Zhang, PhD; Jeph Herrin, PhD; Brian T. Denton, PhD; Jennifer E. Mason, PhD; Victor M. Montori, MD; Steven A. Smith, MD; Nilay D. Shah, PhD
Medicaid-Insured and Uninsured Were More Likely to Have Diabetes Emergency/Urgent Admissions
Monica A. Fisher, PhD, DDS, MPH, MS; and Zhen-qiang Ma, MD, MPH, MS
Roles of Prices, Poverty, and Health in Medicare and Private Spending in Texas
Chapin White, PhD; Suthira Taychakhoonavudh, PhD; Rohan Parikh, MS; and Luisa Franzini, PhD
Measuring Patient-Centered Medical Home Access and Continuity in Clinics With Part-Time Clinicians
Ann-Marie Rosland, MD, MS; Sarah L. Krein, PhD, RN; Hyungjin Myra Kim, ScD; Clinton L. Greenstone, MD; Adam Tremblay, MD; David Ratz, MS; Darcy Saffar, MPH; and Eve A. Kerr, MD, MPH

Annual Diabetic Eye Examinations in a Managed Care Medicaid Population

Elham Hatef, MD, MPH; Bruce G. Vanderver, MD, MPH; Peter Fagan, PhD; Michael Albert, MD; and Miriam Alexander, MD, MPH
We assessed challenges and barriers to annual diabetic eye examinations for a managed care Medicaid population and make recommendations to improve population-level screening.
Objectives: To assess how well a managed care organization performed annual diabetic eye screening in a Medicaid population, and to identify barriers to completion.

Study Design: Cross-sectional study.
Methods: Healthcare claims data for all Medicaid patients with diabetes covered by Priority Partners Managed Care Organization in 2010 and 2012 were collected, and the annual rates for diabetic eye exams in those years were reported. Predictors of completion of the diabetic eye exam in primary care clinics in 2010 and 2012 were assessed using a logistic regression model.

Results: We identified 8902 Medicaid patients with a diagnosis of diabetes using the Healthcare Effectiveness Data and Information Set codes: 3838 patients in 2010 and 5064 patients in 2012. In 2010 and 2012, 46% and 64% of patients, respectively, had completed their annual diabetic eye exam. The increase in participation in annual eye exams from 2010 to 2012 was statistically significant (P <.001). Among the factors increasing the likelihood of completion of an annual diabetic eye exam among the Medicaid population were access to a nonmydriatic fundoscopic camera in the primary care clinic, compliance with glycated hemoglobin measurement based on the recommended guidelines, incentives offered to primary care offices, and higher resource utilization band score. Financial incentives to patients, however, lowered the completion rate.

Conclusions: Annual diabetic eye exam completion is low among the Medicaid population. Detecting high-risk patients and adjusting for factors that play a role in nonadherence both increase the rate of annual diabetic eye exams among underserved populations such as Medicaid patients.

Am J Manag Care. 2015;21(5):e297-e302
Take-Away Points
An annual diabetic eye exam is the main strategy to screen for vision-threatening diabetic retinopathy (DR). To improve screening rates of an at-risk population, we
recommend the following interventions:
  • Application of telemedicine technology, if available.
  • Financial incentives for physicians.
  • Improvement of diabetes control, including increase in compliance with glycated hemoglobin measurement and better treatment coverage for systemic disease. 
To reduce diabetes-related eye disease, we recommend the design of a referral system for patients with positive DR to an ophthalmology service for future followup and treatment.
The number of patients with diabetes worldwide is increasing, and is predicted to double from 171 million in 2000 to more than 366 million by 20301—the World Health Organization (WHO) predicts that diabetes will be the seventh-leading cause of death in the world in 2030.2 In 2012 in the United States, an estimated 29.1 million people, or 9.3% of the population, had diabetes.3 Diabetic retinopathy (DR) is one of the leading causes of blindness in the United States and other developed countries.3,4 Annual diabetic eye exams and prompt treatment, if needed, are considered the key strategies to control vision loss due to diabetes; early detection and appropriate timely intervention for DR would result in a greater than 90% reduction in blindness due to diabetes.5 In the United States, about 50% of people with diabetes do not receive an annual eye exam for early detection and treatment of DR, and many of those with DR who would benefit from laser treatment fail to receive such care.6-11 Although about 98% of patients with diabetes see their primary care physician or endocrinologist at least once a year, the number is much lower for ophthalmology visits.12 Risk factors for inadequate eye care include older age, lower socioeconomic status, lower educational attainment, living in a rural area, shortage of eye care specialists, lack of healthcare insurance, and receiving medical care from a family medicine physician or general practitioner.11,13-15

Different DR screening programs with various levels of effectiveness have been tested in the United States and around the world, including healthcare services located in shops, workplaces, residences, or schools, as well as the provision of mobile health vans and telemedicine technology. None of these alternative approaches involve experienced physicians or, more specifically, an ophthalmologist or retina specialist on-site.12

Johns Hopkins HealthCare (JHHC) was created in 1995 as a partnership between the Johns Hopkins Health System and the Johns Hopkins University School of Medicine to develop and administer contractual healthcare relationships in a managed care organization construct. JHHC boasts a unique care management program to provide support for members with chronic conditions. In 2011, JHHC planned to increase the completion rate for annual diabetic eye exams for Medicaid diabetic patients. To achieve this, JHHC provided nonmydriatic fundoscopic cameras to 3 clinics in the Baltimore area in 2011 and 2012. The camera made it possible to take retinal images of eligible diabetic patients during the time of their primary care visit without the need for pupil dilation. The images were reviewed by retina specialists at Wills Eye Institute in Philadelphia and results were scanned into patients’ charts; patients were then informed about the results of the scan by their primary care physicians. Data on the screening for annual diabetic eye exam by using nonmydriatic camera were collected as well, including how many patients took advantage of the opportunity and factors that seemed to influence them in completing the screening. JHHC also offered financial incentives to primary care practices and to patients who completed the annual diabetic eye exam, and expanded its care management program for Medicaid patients.

In this report, we assess the completion rate for annual diabetic eye exam among Medicaid patients as well as barriers to full coverage, comparing data from 2010 and 2012.


Healthcare claims data were collected for all Medicaid diabetic patients covered by JHHC in 2010 and 2012—the years before and after 2011, when the JHHC instituted its program to increase the completion rate for annual diabetic eye exams. To define diabetes and annual diabetic eye exam screening, we applied the Healthcare Effectiveness Data and Information Set (HEDIS) codes defined by the National Committee for Quality Assurance.16

HEDIS defined diabetic patients in the Medicaid program as “those Medicaid members aged 18 to 75 years with diabetes (type 1 and type 2) and no more than 1 gap in enrollment of up to 45 days during the measurement year. To determine continuous enrollment for a Medicaid beneficiary for whom enrollment is verified monthly, the member may not have more than a 1-month gap in coverage (ie, a member whose coverage lapses for 2 months [60 days] is not considered as continuously enrolled). Two methods identify members with diabetes: pharmacy data and claim/encounter data. The organization must use both to identify the eligible population, but a member only needs to be identified in 1 to be included in the measure. Members may be identified as having diabetes during the measurement year or the year prior to the measurement year.”17

Procedures and Measures

We assessed the effect of several factors on the rate of diabetic eye exams in the primary care setting. We compared the completion rates for diabetic eye exams in 2010 and 2012, while adjusting for factors such as access to a nonmydriatic camera (based on the clinic to which patients were assigned); gender (as documented in claims data); age (date of birth as documented in claims data); compliance with recommended glycated hemoglobin (A1C) measurements (collected from claims data for this specific measurement); financial incentive offer to primary care physicians; financial incentive offer for patients who completed annual diabetic eye exam; medication possession rate (MPR; collected from pharmacy claims data); and resource utilization band (RUB) score as defined by the Johns Hopkins Adjusted Clinical Group Mix System (the ACG System).18 The ACG System as a predictor of healthcare utilization has been validated in multiple settings.19,20 The RUB values are: 0 (no or only invalid diagnosis); 1 (healthy users); 2 (low); 3 (moderate); 4 (high); and 5 (very high users).

The incentive for both providers and patients was $25. Those providers deemed to be eligible to receive the incentive were those who cared for a high volume of JHHC patients; the intent was to phase in incentives to lower-volume providers over time. The patient incentive was available only to those cared for by eligible providers.

Statistical Analysis

We performed descriptive and univariate analysis to assess the completion rate for diabetic eye exams in 2010 and 2012. We also performed multivariate logistic regression analysis to evaluate potential factors that affected compliance with the recommended annual diabetic eye exam.


We identified 8902 Medicaid patients with a diagnosis of diabetes using HEDIS codes: 3838 patients in 2010, and 5064 patients in 2012. Table 1 presents the demographic and baseline characteristics of participants in both years. In 2012, 50% of primary care provider offices and 87% of patients received the opportunity to collect incentives to complete the diabetic eye exam. There were no offers for incentives to physicians and patients in 2010. The MPR scores for diabetic medications in 2010 and 2012 were 0.76 and 0.77, respectively; the difference was not statistically significant (P = .778). In 2010, RUB was moderate for 39% of patients, high for 29%, and very high for 26%. In 2012, RUB was moderate for 39%, high for 30%, and very high for 25% of patients.

Table 2 presents the result of a multivariate logistic regression model for compliance with the annual diabetic eye exam, reporting the odds ratio (OR), 95% CI, and P value for each of the covariates in the model. The OR for completing the annual diabetic eye exam was 2.49 (95% CI, 2.10-2.95) comparing 2012 with 2010 (P <.001). Patients assigned to clinics with access to a nonmydriatic camera had an OR of 1.51 (95% CI, 1.05-2.15) for completing their annual diabetic eye exam compared with those patients in clinics without access to a nonmydriatic camera (P = .024). The OR of having an annual diabetic eye exam versus not having an exam was 1.01 (95% CI, 1.01-1.02) with each 1-year increase in age (P <.001). Patients with successful A1C control had an OR of 1.52 (95% CI, 1.00-2.31) for completing their annual diabetic eye exam compared with those who were not compliant with A1C measurement (P = .047). When an incentive was offered to primary care physicians to complete annual diabetic eye exams for their eligible patients, the OR of having the exam was 1.82 (95% CI, 1.55-2.14) compared with those patients whose primary care physicians did not get an offer of an incentive (P <.001).

When incentives were offered to eligible patients to complete their annual diabetic eye exam, the OR of completing the exam was 0.27 (95% CI, 0.19-0.37) compared with those eligible patients who did not get an offer of an incentive (P <.001). Comparing low, moderate, high, and very high RUB patients with healthy users, the OR for completing the annual diabetic eye exam was 1.05 (95% CI, 0.59-1.85), 4.29 (95% CI, 2.80-6.58), 6.80 (95% CI, 4.41-10.50), and 5.16 (95% CI, 3.34-7.97), respectively (P = .857, <.001, <.001, and <.001, respectively).


There are expected to be 30.3 million adults with diabetes in the United States by 2030,1 with the cost of their care predicted to outpace the rate of population growth.21 DR is one of the leading causes of blindness in the United States; between 2005 and 2008, the estimated prevalence of DR and vision-threatening DR among US adults with diabetes was 28.5% and 4.4%, respectively.4 The key strategies to control vision loss due to diabetes include annual diabetic eye exam screening and prompt treatment if needed. Screening for DR is among several cost-saving preventive measures for diabetic patients,22 so annual diabetic eye exams have been implemented in national health systems in numerous European countries. The British National Health System (NHS) incorporated the screening for diabetic retinopathy in 2008 and used it as a performance measure of overall quality of care.23,24 As part of its “quality assurance standards,” the NHS aimed for

the following key performance indicators; equal or more than 70% of screening uptake; equal or more than 70% of issuing results within 3 weeks of screening; and equal or more than 80% specialist consultation for screen positive tests.25 Studies have shown a decline in sight-threatening DR at second or subsequent screening.26

In the United States, the annual diabetic eye exam is not available for almost one-third of patients with diabetes at high risk for vision loss, and treatment is available for less than 40% of those at high risk for vision loss.11,14 The low rate of DR screening and treatment is not limited to the United States, however. Based on a WHO report in 2006, only an estimated 20% of diabetic patients with sight-threating proliferative DR had 4 ophthalmology visits (with fundus exam) in a 5-year period.12 In the current study in 2010, 46% of Medicaid population had the recommended annual diabetic eye exam, and it increased to 64% across our Medicaid population in 2012.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up